ResearchRSSMay 15
A company called Cereno Scientific is working with PHA Europe & Global to design new pulmonary hypertension medicines in a way that includes patient input. Instead of just scientists deciding how to develop drugs, patients with pulmonary hypertension will have a say in the process from start to finish. This partnership means the final medications may work better for the people who actually need them.
WHY IT MATTERSPatients with pulmonary hypertension will now have direct input into how new treatments are designed, potentially resulting in drugs that better address their real-world needs and concerns.
AdvocacyRSSApr 22
Three organizations that work with facioscapulohumeral muscular dystrophy (FSHD) patients are joining together to make clinical trials better. FSHD is a rare muscle disease that causes weakness in the face, shoulders, and upper arms. This partnership wants to improve how these trials are designed so they can test new treatments more effectively.
WHY IT MATTERSBetter-designed clinical trials mean faster progress toward treatments for FSHD, and patient input through the FSHD Society ensures trials are structured in ways that actually work for people living with the disease.
PolicyPUBMEDApr 1
A European network for rare connective tissue diseases has created a new model where patients are treated as equal partners in research and care decisions. Instead of doctors alone deciding what to study and how to treat patients, this network includes patients in every step—from identifying problems to writing research papers together. This approach helps address long diagnostic delays and gaps in care that patients with these rare diseases often face.
WHY IT MATTERSPatients with rare connective tissue diseases can now directly influence research priorities and treatment approaches through structured partnership roles, rather than having decisions made without their input.
AdvocacyPRESS RELEASEMar 26
NORD and OpenEvidence announced a partnership to create AI-powered tools that help doctors and patients find reliable information about rare diseases. These tools will use artificial intelligence to organize and review medical information, making it easier for people with rare diseases to access trustworthy resources and get better care.
WHY IT MATTERSThis partnership expands access to expert-reviewed rare disease information through AI technology, potentially helping patients with any rare disease find accurate medical resources and connect with specialists more easily.
AdvocacyRSSMar 26
NORD, a major rare disease organization, is partnering with OpenEvidence to create AI-powered tools that help doctors and patients find reliable information about rare diseases. This partnership aims to make it easier for people worldwide to access trustworthy resources about their conditions and treatment options.
WHY IT MATTERSThis partnership could help patients with rare diseases get faster access to accurate, expert-reviewed information from their doctors, potentially reducing diagnostic delays and improving treatment decisions.